trial

Antipsychotic Effects of Oxytocin

NCTId NCT01621737
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 42 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2018-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
42 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-06
Primary completion
2018-12
Eligibility
ALL · 21 Years

Interventions & indications

Drugs
Oxytocin

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

2
David J. Miklowitz, Ph.D.Principal Investigator
Steven G Potkin, MDPrincipal Investigator

Sites

2 total
Irvine, United StatesSan Diego, United States

Facts & assertions

4 sourced
Enrollment
42
Phase
NA
Primary Completion Date
2018-12
Status
TERMINATED
relationships
The graph out of here
drug
Oxytocin
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David J. Miklowitz, Ph.D.
person
Steven G Potkin, MD
person